肠易激综合征中短链脂肪酸富集代谢型的临床相关性
该研究对中重度腹泻型肠易激综合征(IBS-D)患者基线数据行横断面探索性分析,通过粪便挥发性有机化合物谱识别出短链脂肪酸(SCFA)富集代谢型,占31.7%(20/63),并与更严重腹痛、便急、排便频率增加及全肠道传输加快相关。
要点
- 中重度IBS-D患者中可识别出SCFA富集代谢型,占31.7%(20/63)。
- SCFA富集代谢型与更严重腹痛、便急、排便频率增加及全肠道传输加快相关。
- SCFA相对丰度与症状严重度正相关、与传输时间负相关。
核心结论
- 粪便SCFA富集代谢型与以疼痛、便急、快速传输和排便频率增高为特征的IBS-D表型相关。
研究设计与样本
- 为多中心随机安慰剂对照昂丹司琼治疗IBS-D试验(TRITON)基线数据的post hoc横断面探索性分析。
- 粪便挥发性有机化合物采用GC-MS分析,微生物组采用全基因组鸟枪法宏基因组测序。
- 采用无监督层次聚类识别SCFA富集代谢型,并用非负矩阵分解(NMF)推导代谢特征。
主要发现
- 63名参与者中20名(31.7%)被识别为SCFA富集代谢型。
- 该代谢型与更严重腹痛、便急、排便频率增加及更快全肠道传输相关。
- NMF识别出三种代谢特征:S3以高比例SCFA为特征并对应SCFA富集代谢型,S1和S2对应非SCFA(Other)代谢型。
- SCFA相对丰度与症状严重度正相关,与传输时间负相关。
- Other代谢型及S1/S2特征富集与较慢传输相关的分类群,S3与SCFA代谢型无重叠分类群。
临床怎么用
- 对中重度IBS-D患者可关注SCFA富集代谢型,其与更重症状及更快传输相关,或有助于表型分层。
局限性
- 为post hoc横断面探索性分析,样本量有限(63例),不能推断因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metabolomic analysis in irritable bowel syndrome (IBS) has identified metabotypes enriched in faecal short-chain fatty acids (SCFAs), but it remains unclear whether this reflects rapid colonic transit or if these metabolites actively contribute to pathophysiology. AIMS: We aimed to determine whether an SCFA metabotype could be identified within a cohort of patients with moderate-severe IBS-D and assess whether this metabotype associated with greater clinical severity, alterations in gut transit time and specific microbiome features. METHODS: This was a post hoc cross-sectional exploratory analysis of baseline data from the multicentre, randomised, placebo-controlled trial of ondansetron in IBS-D (TRITON: ISRCTN17508514). Faecal volatile organic compounds were profiled by GC-MS. The microbiome was characterised by whole-genome shotgun metagenomic sequencing. Unsupervised hierarchical clustering was used to identify an SCFA-enriched metabotype and non-negative matrix factorisation (NMF) enabled the derivation of complementary metabosignatures by assessing continuous gradients in metabolite composition. RESULTS: A SCFA-enriched metabotype was identified in 20/63 participants (31.7%). This metabotype was associated with more severe abdominal pain, urgency, increased stool frequency and faster whole-gut transit. NMF identified three metabosignatures: S3 was typified by a high proportion of SCFAs and captured the SCFA-enriched metabotype, while S1 and S2 corresponded to the non-SCFA ("Other") metabotype. SCFA relative abundance positively correlated with symptom severity and inversely correlated with transit time. The Other metabotype and S1/S2 signatures were enriched in taxa linked to slower transit, whereas S3 showed no overlapping taxa with the SCFA metabotype. CONCLUSION: A faecal metabotype enriched in SCFAs associated with an IBS-D phenotype characterised by pain, urgency, rapid transit and higher stool frequency.
引用
- Conley TE, Duncan A, Modasia A, et al. The Emerging Short Chain Fatty Acid Enriched Metabotype in Irritable Bowel Syndrome and Its Potential Clinical Relevance. Aliment Pharmacol Ther. 2026. PMID: 41995478. doi:10.1111/apt.70677
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。